Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolios

Dicerna Pharmaceuticals Inc (DRNA)

Currency in USD
DRNA Scorecard
Fair Value
Day's Range
52 wk Range
Prev. Close
Day's Range
52 wk Range
Average Volume (3m)
1-Year Change
Shares Outstanding
Fair Value
Dividends Payment Streak
Strong Sell
Strong Buy
Strong Sell
How do you feel today about DRNA?
Vote to see community's results!

Dicerna Pharmaceuticals Inc Company Profile

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of ribonucleic acid interference (RNAi)-based pharmaceuticals. It develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, chronic liver, and complement-mediated diseases, as well as neurodegenerative diseases and pain. The company’s principal development programs include Nedosiran for primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; Belcesiran for alpha-1 antitrypsin deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. It has collaboration agreements with Novo Nordisk A/S; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Eli Lilly, and Company; Alexion Pharmaceuticals, Inc.; Boehringer Ingelheim International GmbH; and Alnylam Pharmaceuticals, Inc. Dicerna Pharmaceuticals, Inc. was formerly known as Oncorna Pharmaceuticals, Inc. and changed its name to Dicerna Pharmaceuticals, Inc. on April 19, 2007. The company was incorporated in 2006 and is based in Lexington, Massachusetts with additional offices in Boulder, Colorado, and Lexington, Massachusetts. As of December 28, 2021, Dicerna Pharmaceuticals, Inc. operates as a subsidiary of Novo Nordisk A/S.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.